dbACP: A Comprehensive Database of Anti-Cancer Peptides

340 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00005 Citropin modified peptide-3 GLFAVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 6 M
dbacp00014 Citropin modified peptide-5 GLFDVIKAVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 100 µM
dbacp00023 Citropin modified peptide-7 GLFDVIKKVAAVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00035 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 6.5% inhibition at 10-6 M
dbacp00036 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-5 M
dbacp00037 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.5% inhibition at 10-4 M
dbacp00038 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-3 M
dbacp00061 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.9% inhibition at 10-5 M
dbacp00062 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00086 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.0% inhibition at 10-6 M
dbacp00087 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.7% inhibition at 10-5 M
dbacp00088 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.7% inhibition at 10-4 M
dbacp00089 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00102 Citropin modified peptide-11 GLFDVIKKVASVIKGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00111 Citropin modified peptide-13 GLFDVIKKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00120 Citropin modified peptide-14 GLFDVIAKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00133 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.6% inhibition at 10-6 M
dbacp00134 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.9% inhibition at 10-5 M
dbacp00135 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 5.9% inhibition at 10-4 M
dbacp00136 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 17.9% inhibition at 10-3 M
dbacp00154 Citropin modified peptide-15 GLFAVIKKVASVIKGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00167 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.2% inhibition at 10-5 M
dbacp00168 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.3% inhibition at 10-4 M
dbacp00169 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 19.4% inhibition at 10-3 M
dbacp00187 Citropin modified peptide-16 GLFAVIKKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00200 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 0.8% inhibition at 10-6 M
dbacp00201 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.4% inhibition at 10-5 M
dbacp00202 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-4 M
dbacp00203 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 18.3% inhibition at 10-3 M
dbacp00221 Citropin modified peptide-17 GLFAVIKKVAAVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00234 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-6 M
dbacp00235 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.5% inhibition at 10-5 M
dbacp00236 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 11.4% inhibition at 10-4 M
dbacp00237 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 23.2% inhibition at 10-3 M
dbacp00256 Citropin modified peptide-18 GLFAVIKKVAAVIRRL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00265 Citropin modified peptide-19 GLFAVIKKVAKVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00274 Citropin modified peptide-22 GLFKVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00282 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.1% inhibition at 10-6 M
dbacp00283 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 70.7% inhibition at 10-5 M
dbacp00284 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 34.4% inhibition at 10-3 M
dbacp00296 Citropin modified peptide-23 GLFKVIKKVAKVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp00774 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 4.3 µMo/L
dbacp00779 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 5.2 µMo/L
dbacp00782 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 8.7 µMo/L
dbacp00787 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 4.4 µMo/L
dbacp00790 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 7.2 µMo/L
dbacp00795 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 4.6 µMo/L
dbacp00798 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 6.5 µMo/L
dbacp00803 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 7.8 µMo/L
dbacp00999 Alloferon 1 HGVSGHGQHGVHG Blow fly Cell membrane disintegration Not specified Not found Skin cancer Not found
dbacp01256 Aurein 3.1 GLFDIVKKIAGHIAGSI Southern bell frog, Australia Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10-100 µM
dbacp01265 Aurein 3.1 GLFDIVKKIAGHIAGSI Southern bell frog, Australia Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10-100 µM
dbacp01275 Aurein 3.2 GLFDIVKKIAGHIASSI Southern bell frog, Australia Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10 µM
dbacp01285 Aurein 3.3 GLFDIVKKIAGHIVSSI Southern bell frog, Australia Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10 µM
dbacp01315 Aurein-2.5 MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE Green and golden bell frog Not specified Not specified Not found Skin cancer Not found
dbacp01324 Aurein-2.5 GLFDIVKKVVGAFGSL Green and golden bell frog Not specified Not specified Not found Skin cancer Not found
dbacp01410 Aurein1.2 GLFDIIKKIAESF Southern bell frog Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10 µM
dbacp01419 Aurein2.5 GLFDIVKKVVGAFGSL Southern bell frog Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10 µM
dbacp01428 Aurein2.6 GLFDIAKKVIGVIGSL Southern bell frog Cell membrane disruption Not specified Skin tumor cell line Skin cancer LC50 : 10 µM
dbacp01533 BC46 c[(bA)(bA)RKD] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01538 BC48 c[(bA)GRKD] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01543 BC49 c[(bA)(4aba)RKD] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01548 BC50 c[(4aba)(bA)RKD] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01553 BC70 c[(bA)(k)RKD(1-D-NAl)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01558 BC71 c[(bA)(k)RKD(2-D-NAl)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01563 BC72 c[(bA)(o)RKD(f)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01568 BC74 c[(bA)(k)(Fguan)KD(f)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01573 BC75 c[(bA)(k)RKD(D-Bip)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01578 BC81 c[(2233tmpa)(k)RKD(2-D-NAl)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01583 BC83 c[(bA)(k)RKD(D-2Anth)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp01588 BC84 c[(bA)(k)RKD(w)] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp02018 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay LOXIMVI Skin cancer IC50 : 9.5 µg/ml
dbacp02019 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MALME-3M Skin cancer IC50 : 10.9 µg/ml
dbacp02020 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay M14 Skin cancer IC50 : 15.1 µg/ml
dbacp02021 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 11.1 µg/ml
dbacp02022 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-MEL-5 Skin cancer IC50 : 8.9 µg/ml
dbacp02023 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay UACC-257 Skin cancer IC50 : 12.5 µg/ml
dbacp02024 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay UACC-62 Skin cancer IC50 : 10.6 µg/ml
dbacp02160 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :10.6 ± 0.4 µM
dbacp02161 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :13.0 ± 1.0 µM
dbacp02162 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :12.1 ± 1.6 µM
dbacp02163 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :37 ± 4.3 µM
dbacp02164 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 10.6 ± 0.4 µM
dbacp02165 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.0 ± 1.0 µM
dbacp02166 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.1 ± 1.6 µM
dbacp02167 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 3.7 ± 4.3 µM
dbacp02181 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02182 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02183 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02184 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02185 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02186 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02187 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02188 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02202 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02203 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02204 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02205 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02206 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02207 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02208 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02222 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02270 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay B16-F10 Skin cancer LC50 : 1.75 µM
dbacp02273 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay WM1158 Skin cancer LC50 : 4.1 µM
dbacp02338 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC12 Skin cancer IC50 : 1 µM
dbacp02339 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC25 Skin cancer IC50 : 2.2 µM
dbacp02340 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 0.6 ± 0.6% cell growth inhibition at 10 µM
dbacp02341 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 107.0 ± 5.0% cell growth inhibition at 1 µM
dbacp02492 Citropin 1.1 GLFDVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp02503 Citropin 1.1D glfdvikkvasviggl Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp02550 CPF-ST3 GLLGPLLKIAAKVGSNLL Diploid clawed frog, Western clawed frog,Africa Cell membrane disintegration Not specified Not found Skin cancer Not found
dbacp02551 CPF-ST3 GLLGPLLKIAAKVGSNLL Diploid clawed frog, Western clawed frog,Africa Cell membrane disintegration Not specified Not found Skin cancer Not found
dbacp02933 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay NIH/3T3 Skin cancer IC50 : 13 µM
dbacp02936 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay B16F10 Skin cancer IC50 : 10.5 µM
dbacp02939 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay MCF Skin cancer IC50 : 13.7 µM
dbacp02942 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay HeLa Skin cancer IC50 : 11.1 µM
dbacp02951 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay B16F10 Skin cancer IC50 : 12.8 µM
dbacp02953 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay MCF-7 Skin cancer IC50 : 15.3 µM
dbacp02977 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 27.39 µM
dbacp02984 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 27.39 µM
dbacp02991 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 :22.25 µM
dbacp02998 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 22.25 µM
dbacp03005 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.97 µM
dbacp03012 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.97 µM
dbacp03019 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.16 µM
dbacp03026 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.16 µM
dbacp03159 GR01 c[CRKDC]Disulfidebridge AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp03164 GR16 c[KRKDF] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp03169 GR35 c[KRAAF] AMOP domain of ISM trigger apoptosis Inducing apoptosis LDH assay HUVECs Skin cancer Not found
dbacp03529 KW5 KAAKKAAKAAKKAAKAAKKAA Bovine lactoferrin (Lf-B) Through interactions with the plasma membrane MTT/MTS assay FEMX Skin cancer IC50 : 30 ± 3 µM
dbacp03549 L1 PEWFKCRRWQWRMKKLGA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : > 404 µM
dbacp03552 L10 PAARKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 24 µM
dbacp03555 L11 PAARKAARWAWRMLKKGA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 116 µM
dbacp03558 L12 PAWRKAFRWAKRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 7.9 µM
dbacp03561 L13 PAWRKAFRKAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 14 µM
dbacp03564 L14 PAWRKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 125 µM
dbacp03567 L15 PAWRKARRWARRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 87 µM
dbacp03571 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03576 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : > 83.6 µMo/L
dbacp03579 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03584 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : >83.6 µMo/L
dbacp03586 L2 PAWFKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 144 µM
dbacp03590 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 59.8 µMo/L
dbacp03595 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 63.5 µMo/L
dbacp03597 L3 PAWRKAFRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 32 µM
dbacp03600 l3,10,13K7,8K4R2L9 KLlRLLkkLlRLlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay B16-F10 Skin cancer LC50 : 2.5 µM
dbacp03602 l3,4,8,10K5L7 KlllKLKlKlLK Diastereomeric peptide Plasma membrane perturbation; Necrosis XTT assay B16-F10 Skin cancer LC50 : 100 µM
dbacp03604 L4 PAWFKARRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 31 µM
dbacp03607 L5 PAWRKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 6.6 µM
dbacp03610 L6 PAWRKAFRWAARMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 11 µM
dbacp03614 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 58.7 µMo/L
dbacp03619 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 62.5 µMo/L
dbacp03622 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : >83.6 µMo/L
dbacp03627 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : >83.6 µMo/L
dbacp03629 L7 PAWRKAFRAAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 16 µM
dbacp03632 L8 PAWAKAFRAAARMKLKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 110 µM
dbacp03635 L9 PAWRKAARWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 35 µM
dbacp03733 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay FEMX Skin cancer IC50 : 40 ± 7 µM
dbacp03735 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay KMS-5 Skin cancer IC50 : 38 µM
dbacp03737 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay KMM-1 Skin cancer IC50 : 57 µM
dbacp03738 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay Sudhl-4 Skin cancer IC50 : 16 µM
dbacp04302 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay B16F1 Skin cancer IC50 : 13.3 µM
dbacp04303 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay A375 Skin cancer IC50 : 12.7 µM
dbacp04304 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : 15.3 µM
dbacp04308 LTX-328 KAQ-Dip-QKQAW Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : >350 µM
dbacp04442 Maculatin 1.3 GLLGLLGSVVSHVVPAIVGHF Blue-thighed frog, Australia Cell membrane disruption Not specified Not found Skin cancer Not found
dbacp04453 Maculatin 1.4 GLLGLLGSVVSHVLPAITQHL Blue-thighed frog, Australia Cell membrane disruption Not specified Not found Skin cancer Not found
dbacp04631 MCL-1, BH3 (208-228) KALETLRRVGDGVQRNHETAF Anti apoptotic (MCL-1, BFL1) Inducing apoptosis Not specified Not found Skin cancer Not found
dbacp04643 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :3.2 ± 0.1 µM
dbacp04644 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :2.1 ± 0.1 µM
dbacp04645 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.8 ± 0.1 µM
dbacp04646 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.4 ± 0.1 µM
dbacp04647 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.4 ± 0.1 µM
dbacp04648 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 3.2 ± 0.1 µM
dbacp04649 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 2.1 ± 0.1 µM
dbacp04650 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.8 ± 0.1 µM
dbacp04651 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.4 ± 0.1 µM
dbacp04652 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Main component of honey bee venom Membrane damage; Apoptotic cell death; Necrosis Cell viability assay SCC25 Skin cancer 102.9 ± 4.1% cell growth inhibition at 1 µM
dbacp04701 mPep1 RKAFRWAWRMLKKAAPSITCVR Bovine lactoferrin (Lf-B) Necrotic cell death by destroying cellular membrane structure; Apoptotic cell death MTT/MTS assay HL-60 Skin cancer IC50 :8 µM
dbacp04851 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04852 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04853 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04854 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04855 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM
dbacp04856 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04857 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04858 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM
dbacp04859 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 4.3±0.3 µM
dbacp04860 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM (approx.)
dbacp04861 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM (approx.)
dbacp04862 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM (approx.)
dbacp04863 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM (approx.)
dbacp04880 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04881 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04882 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04883 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp05022 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 17.8 µMo/L
dbacp05027 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 11.5 µMo/L
dbacp05038 P18 KWKLFKKIPKFLHLAKKF Bovine lactoferrin (Lf-B) Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 92.2 ± 1.02% cell viability at 10 µM
dbacp05039 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 71.1 ± 2.84% cell viability at 20 µM
dbacp05040 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 50 ± 3.09% cell viability at 40 µM
dbacp05041 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 31.5 ± 1.49% cell viability at 60 µM
dbacp05042 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 13.8 ± 1.44% cell viability at 80 µM
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp05094 P7 PLLQATLGGGS Not found Apoptosis inducing WST-1 assay B16-F10 Skin cancer IC50 : 1 µM
dbacp05441 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay B16F10-Nex 2 Skin cancer At 100 µM 50% viablity
dbacp05442 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay A-2058 Skin cancer At100 µM 30% viablity
dbacp05443 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-25 Skin cancer At 100 µM 55 - 60% viablity
dbacp05444 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-28 Skin cancer At 100 µM 35 - 40% viablity
dbacp05938 Retro LGGIVSAVKKIVDFLG Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Skin tumor cell line Skin cancer IC50 : 5 M
dbacp06404 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 49.4% Cytotoxic at 0.1 µg/ml
dbacp06405 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 51.2% Cytotoxic at 1 µg/ml
dbacp06406 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 53.0% Cytotoxic at 10 µg/ml
dbacp06407 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 61.2% Cytotoxic at 100 µg/ml
dbacp06496 Vibi G GTFPCGESCVFIPCLTSAIGCSCKSKVCYKN Alpine violet, Viola biflora Cell membrane disintegration Not specified Not found Skin cancer Not found
dbacp06548 Z1 KAAKKWAKAAKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06551 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06554 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06567 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : >211 µM
dbacp06570 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 155 µM
dbacp06583 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 42 µM
dbacp06586 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 17 µM
dbacp06589 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 15 µM
dbacp06592 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 19 µM
dbacp06595 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 9 µM
dbacp06735 NKL-WT KLKSKLMVVCNKIGLLKSLCRKFVKSH Trematomus bernacchii Apoptosis inducing luciferase-based ATPlite assay B16-F10 Skin Cancer ATP level = 0.753 ± 0.254 at 40 μM
dbacp06736 NKL-MUT KLKSKLMVVANKIGLLKSLARKFVKSH Trematomus bernacchii Apoptosis inducing luciferase-based ATPlite assay B16-F10 Skin Cancer ATP level = 0.023 ± 0.007 at 40 μM
dbacp06802 A11 EYVQTVKSSKG Annexin A1 Targeting PD-L3 Biotin Pull Down assay A-375 Skin Cancer Not Available
dbacp06804 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.3 ± 0.2 μM
dbacp06810 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 μM
dbacp06816 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 3.0 ± 0.1 μM
dbacp06820 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 4.6 ± 0.2 μM
dbacp06826 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 μM
dbacp06832 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 10.3 ± 1.1 μM
dbacp06838 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MM96L Skin Cancer CC50 = 5.4 ± 0.3 μM
dbacp06975 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay A-431 Skin Cancer 10 % cell viability at 0.05 wt %
dbacp07008 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay A-375 Skin Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07014 Sansalvimide A LXVLF Fusarium sp. Not Available Not Available SK-MEL-2 Skin Cancer IC50 = 5.9 µg/ml
dbacp07029 [G10a]-SHa FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MNT-1 Skin Cancer IC50 = 15.25 ± 0.80 µM
dbacp07036 [G10a]2-SHa FLSGIVGMLaKLFKFLKaLMFLSGIVG Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MNT-1 Skin Cancer IC50 = 4.72 ± 0.36 µM
dbacp07043 [G10a]3-SHa FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MNT-1 Skin Cancer IC50 = 2.24 ± 0.05 µM
dbacp07049 Jeff-[G10a]2-SHa FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MNT-1 Skin Cancer IC50 = 57.03 ± 6.09 µM
dbacp07239 RB4 MADSERLSAPGCWAACTNFSRTRK Derived from protein PLP2 F-actin modulation induces necrotic death. MTT assay B16-F10-Nex 2 Skin Cancer EC50 = 0.263 ± 0.585 mol/L × 10-3
dbacp07242 RB4 MADSERLSAPGCWAACTNFSRTRK Derived from protein PLP2 F-actin modulation induces necrotic death. MTT assay A-2058 Skin Cancer EC50 = 0.744 ± 0.208 mol/L × 10-3
dbacp07322 PCC-1 KKRKKKAFALKFVVDLI Poecilocoris lewisi Sp1 suppression, apoptosis, cell-cycle arrest MTS assay SK-Mel-28 Skin Cancer IC50 = 50.8 µM
dbacp07323 PCC-1 KKRKKKAFALKFVVDLI Poecilocoris lewisi Sp1 suppression, apoptosis, cell-cycle arrest MTS assay G361 Skin Cancer IC50 = 57.8 µM
dbacp07360 N-Ter-TAT RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Synthetic Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 > 50.0 μM
dbacp07361 Pal-N-Ter-TAT Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 = 36.67(Supplementary material)/15.2 ± 0.7 μM(Published paper)
dbacp07364 pFL-N-Ter-TAT FPWWWPFL-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay A-375 Skin Cancer IC50 = 11.1 ± 0.1 μM
dbacp07465 ΔM4 NFFKRIRRAWKRIWKWIYSA Synthetic Membrane disruption triggers mitochondrial apoptosis Not Available A-375 Skin Cancer IC50 = 9.31 μM
dbacp07468 Protonectin ILGTILGLLKGL Parachartergus fraternus Cell penetration without toxic accumulation Resazurin dye assay MM96L Skin Cancer CC50 = 14.8 ± 0.9 µM
dbacp07470 Protonectin-F IFGTILGFLKGL Protonoectin Cell penetration without toxic accumulation Resazurin dye assay MM96L Skin Cancer CC50 = 16.0 ± 1.2 µM
dbacp07493 Figainin 1 FIGTLIPLALGALTKLFK Boana raniceps Membrane disruption, α-helix mediated MTT assay B16-F10 Skin Cancer IC50 = 10.5 µM
dbacp07578 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 125.0 ± 16.8 μM
dbacp07579 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 10.7 ± 0.2 μM
dbacp07580 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 20.9 ± 3.9 μM
dbacp07581 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.2 ± 0.2 μM
dbacp07582 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 2.5 ± 0.1 μM
dbacp07583 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.7 ± 0.2 μM
dbacp07584 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.3 ± 0.3 μM
dbacp07585 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07586 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07587 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 2.7 ± 0.9 μM
dbacp07588 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07589 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07590 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.6 ± 0.3 μM
dbacp07591 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 3.4 ± 0.4 μM
dbacp07592 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 5.0 ± 0.1 μM
dbacp07593 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07594 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07595 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.6 ± 0.7 μM
dbacp07596 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.8 ± 0.4 μM
dbacp07597 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 4.7 ± 0.3 μM
dbacp07598 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.8 ± 0.3 μM
dbacp07648 AP1-Z1 FLFSLIPHAISGLISAFK AcrAP1 from the venom of the Arabian scorpion Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer IC50 = 9.478 μM
dbacp07651 AP1-Z5a FLFKLIPKAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07654 AP1-Z5b FLFKLIKHAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer IC50 = 2.607 μM
dbacp07657 AP1-Z3a FLFSLIKHAIKGLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07660 AP1-Z3b FLFSLIKHAISKLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07663 AP1-Z7 FLFKLIKKAIKKLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07666 AP1-Z9 FLFKLIKKKIKKLIKKFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay A-375 Skin Cancer Graph Figure 2B
dbacp07803 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07804 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.4 ± 0.1 µM
dbacp07805 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07806 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 2.7 ± 0.3 µM
dbacp07810 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 4.3 ± 0.3 µM
dbacp07811 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.4 µM
dbacp07814 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 µM
dbacp07815 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.0 ± 0.2 µM
dbacp07816 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 3.9 ± 0.2 µM
dbacp07817 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 18.9 ± 0.9 µM
dbacp07820 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 17.3 ± 1.0 µM
dbacp07821 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 27.8 ± 2.2 µM
dbacp07822 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 28.2 ± 2.0 µM
dbacp07824 [R9S]cT1 KWCFRVCYSGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 5.3 ± 0.6 µM
dbacp07825 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 µM
dbacp07826 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 2.3 ± 0.2 µM
dbacp07827 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07828 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.3 µM
dbacp07830 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07831 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.2 ± 0.1 µM
dbacp07832 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07833 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 4.5 ± 0.3 µM
dbacp07835 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 11.8 ± 0.9 µM
dbacp07836 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 11.1 ± 0.9 µM
dbacp07838 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.0 ± 0.1 µM
dbacp07839 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07840 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.2 µM
dbacp07843 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07844 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07845 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.9 ± 0.2 µM
dbacp07879 Nubein6.8 LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN Naja nubiae DNA damage and apoptosis induction MTT assay A-375 Skin Cancer EC50 = 0.54 ± 0.04 μM
dbacp07953 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MDA-MB-435S Skin Cancer IC50 = 179.00 µM
dbacp07986 SmacN7-Arg8 fused peptide P4 Ahx-AVPIAQK(KRRRRRRRRRE) Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp07987 SmacN7-Arg8 fused peptide P5 Ahx-(KAVPIAQKE)RRRRRRRR Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp07988 SmacN7-Arg8 fused peptide P7 Ahx-(KAVPIAQKE)GG(KRRRRRRRRE) Synthetic Apoptosis inducing Cell Titer Blue Cell Viability assay U-266 Skin Cancer Cell viability < 50% at 50 μM
dbacp08014 Ec-LDP-hBD1 MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH Synthetic EGFR-targeted defensin induces mitochondrial apoptosis CCK-8 assay A-431 Skin Cancer IC50 = 1.8 μM
dbacp08045 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay B-16 Skin Cancer ED50 = 7.1 μM
dbacp08067 Temporin-PE FLPIVAKLLSGLL Pelophylax kl. esculentus Modulates membrane interactions MTT assay MDA-MB-435S Skin Cancer IC50 = 33.23 μM
dbacp08071 temporin-PEa FLYIVAKLLSGLL Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay MDA-MB-435S Skin Cancer IC50 = 9.864 μM
dbacp08075 temporin-PEb FLPIVAKLLSGLLGRKKRRQRRR Synthetic analog of Temporin-PE Modulates membrane interactions MTT assay MDA-MB-435S Skin Cancer IC50 = 3.483 μM
dbacp08080 APETx4 GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD Anthopleura elegantissima Not Available CellTox Green Dye assay MDA-MB-435S Skin Cancer Green object count < 100 /mm2 at 20 μM
dbacp08167 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay A-375 Skin Cancer IC50 = 5.23 μM
dbacp08174 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 2.6 µM
dbacp08186 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08194 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 3.1 µM
dbacp08202 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 1.9 µM
dbacp08210 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08218 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08226 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08234 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08242 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08250 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08319 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-2058 Skin Cancer Cell Viability = 0.2% at 25 μM
dbacp08330 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 6.7% at 25 μM
dbacp08338 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 87.5% at 25 μM